主催: 公益社団法人日本薬理学会
会議名: 第95回日本薬理学会年会
回次: 95
開催地: Fukuoka
開催日: 2022/03/07 - 2022/03/09
New approaches methodologies (NAMs) have been developed to predict adverse events in humans more accurately. In vitro methods, such as human iPS cell technology, are expected to accelerate the efficiency of drug development and ensure the patients' safety and speed-up of the review process. We have evaluated the iPSC-based tools to assess safety and effectiveness of chemicals from the viewpoint of regulatory science. Based on the current COVID-19 pandemic situation and animal alternative methods, we have made various iPSC models, such as cardiomyocytes, blood-brain barrier, and intestine, to evaluate the effects of COVID-19 drugs. Here we would like to summarize the current status and future perspectives of iPSC-based system for COVID-19 in drug development.